Jinhai Med Tech (02225) announced that on February 25, 2026, Jinhai Biomedical, Shanghai Jinhai, and Shanghai Anbaida Investment entered into a capital contribution agreement. Under this agreement, the shareholders of Jinhai Biomedical have consented to increase its fully paid registered capital from RMB 5 million to RMB 25 million. Shanghai Jinhai and Shanghai Anbaida Investment will provide additional capital contributions totaling RMB 20 million, corresponding to their respective shareholding ratios of 51:49 in Jinhai Biomedical. Jinhai Biomedical intends to focus on the medical products business, including the wholesale and distribution of medical devices. Shanghai Jinhai's contribution will be funded from the Group's internal resources. The capital amount was determined through fair negotiation between Jinhai Biomedical and its shareholders, taking into account the subsidiary's short-term funding requirements for business development and investment opportunities, as well as other financing options available to it. Jinhai Biomedical will continue to be accounted for as a non-wholly-owned subsidiary in the Group's financial statements, both before and after the capital injection. The purpose of the capital contribution agreement is to provide Jinhai Biomedical with additional capital to strengthen its financial position and support its business growth. The directors consider the terms of the contribution to be fair and reasonable, as they are proportionate to the shareholding ratio between Shanghai Jinhai and Shanghai Anbaida Investment.